May 22, 2023 by admin aurigene A highly differentiated PDL1-A2AR dual inhibitor for potential use in cancer therapy
May 2, 2023 by admin aurigene Targeting CBP/p300 – Inhibition vs Degradation for Potent Anti-tumor Efficacy
May 2, 2023 by admin aurigene Amino Acid inspired oral immune checkpoint antagonists for cancer therapy
May 1, 2023 by admin aurigene Oral Immune Checkpoint Antagonist Dually Targeting TIGIT & PD-1 Pathways for Cancer Therapy
May 1, 2023 by admin aurigene Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor
May 1, 2023 by admin aurigene Orally Bioavailable CBP and p300 Selective Degraders for the Treatment of AR- and ER- dependent Cancers
April 28, 2023 by admin aurigene The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets
April 28, 2023 by admin aurigene Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery
